Search

Your search keyword '"M. De Ville De Goyet"' showing total 17 results
Start Over Author "M. De Ville De Goyet"
17 results on '"M. De Ville De Goyet"'

2. Toxicité cardiaque des traitements du cancer chez l’enfant et l’adolescent

Author

M. de Ville de Goyet, Bénédicte Brichard, and Stéphane Moniotte

Subjects
Gynecology, medicine.medical_specialty, Oncology, business.industry, Pediatrics, Perinatology and Child Health, medicine, Hematology, business, Pediatric cardiology
Abstract

Resume Les progres therapeutiques en oncologie pediatrique ont permis de porter la survie a cinq ans pour tous types de cancer confondus a 80 %, permettant a un nombre croissant d’enfants d’etre gueris et d’atteindre l’âge adulte. Cependant, ces survivants de cancers sont a risque de developper des complications secondaires aux traitements. Les anthracyclines et la radiotherapie mediastinale sont potentiellement cardiotoxiques et contribuent a une morbidite et une mortalite significative a long terme. Cette revue resume brievement la physiopathologie des complications cardiaques liees aux anthracyclines et a la radiotherapie, leur incidence, ainsi que les facteurs de risque principaux. Les etudes les plus significatives sont exposees dans cette revue et toutes demontrent un risque accru de complications cardiaques par rapport a la population normale. Enfin, les differentes techniques actuellement disponibles ou emergentes pour le suivi cardiaque des patients, les moyens de prevention pour limiter la cardiotoxicite et les traitements de ces complications cardiaques une fois diagnostiquees seront developpes. Les pathologies cardiovasculaires etant la cause principale de deces chez ces survivants, le depistage d’une dysfonction cardiaque debutante reste la cle de voute du devenir de ces patients.

Published
2013
Full Text
View/download PDF

3. Abstracts

Author

V. Dunet, A. Dabiri, G. Allenbach, A. Goyeneche Achigar, B. Waeber, F. Feihl, R. Heinzer, J. O. Prior, J. E. Van Velzen, J. D. Schuijf, F. R. De Graaf, M. A. De Graaf, M. J. Schalij, L. J. Kroft, A. De Roos, J. W. Jukema, E. E. Van Der Wall, J. J. Bax, E. Lankinen, A. Saraste, T. Noponen, R. Klen, M. Teras, T. Kokki, S. Kajander, M. Pietila, H. Ukkonen, J. Knuuti, A. P. Pazhenkottil, R. N. Nkoulou, J. R. Ghadri, B. A. Herzog, R. R. Buechel, S. M. Kuest, M. Wolfrum, O. Gaemperli, L. Husmann, P. A. Kaufmann, D. Andreini, G. Pontone, S. Mushtaq, L. Antonioli, E. Bertella, A. Formenti, S. Cortinovis, G. Ballerini, C. Fiorentini, M. Pepi, A. S. Koh, J. S. Flores, F. Y. J. Keng, R. S. Tan, T. S. J. Chua, A. D. Annoni, G. Tamborini, M. Fusari, A. L. Bartorelli, S. H. Ewe, A. C. T. Ng, V. Delgado, J. Schuijf, F. Van Der Kley, A. Colli, A. De Weger, N. A. Marsan, K. H. Yiu, A. C. Ng, S. A. J. Timmer, P. Knaapen, T. Germans, P. A. Dijkmans, M. Lubberink, J. M. Ten Berg, F. J. Ten Cate, I. K. Russel, A. A. Lammertsma, A. C. Van Rossum, Y. Y. Wong, G. Ruiter, P. Raijmakers, W. J. Van Der Laarse, N. Westerhof, A. Vonk-Noordegraaf, G. Youssef, E. Leung, G. Wisenberg, C. Marriot, K. Williams, J. Etele, R. A. Dekemp, J. Dasilva, D. Birnie, R. S. B. Beanlands, R. C. Thompson, A. H. Allam, L. S. Wann, A. H. Nureldin, G. Adelmaksoub, I. Badr, M. L. Sutherland, J. D. Sutherland, M. I. Miyamoto, G. S. Thomas, H. J. Harms, S. De Haan, M. C. Huisman, R. C. Schuit, A. D. Windhorst, C. Allaart, A. J. Einstein, T. Khawaja, C. Greer, A. Chokshi, M. Jones, K. Schaefle, K. Bhatia, D. Shimbo, P. C. Schulze, A. Srivastava, R. Chettiar, J. Moody, C. Weyman, D. Natale, W. Bruni, Y. Liu, E. Ficaro, A. J. Sinusas, A. Peix, E. Batista, L. O. Cabrera, K. Padron, L. Rodriguez, B. Sainz, V. Mendoza, R. Carrillo, Y. Fernandez, E. Mena, A. Naum, T. Bach-Gansmo, N. Kleven-Madsen, M. Biermann, B. Johnsen, J. Aase Husby, S. Rotevatn, J. E. Nordrehaug, J. Schaap, R. M. Kauling, M. C. Post, B. J. W. M. Rensing, J. F. Verzijlbergen, J. Sanchez, G. Giamouzis, N. Tziolas, P. Georgoulias, G. Karayannis, A. Chamaidi, N. Zavos, K. Koutrakis, G. Sitafidis, J. Skoularigis, F. Triposkiadis, S. Radovanovic, A. Djokovic, D. V. Simic, M. Krotin, A. Savic-Radojevic, M. Pljesa-Ercegovac, M. Zdravkovic, J. Saponjski, S. Jelic, T. Simic, R. Eckardt, B. J. Kjeldsen, L. I. Andersen, T. Haghfelt, P. Grupe, A. Johansen, B. Hesse, H. Pena, G. Cantinho, M. Wilk, Y. Srour, F. Godinho, N. Zafrir, A. Gutstein, I. Mats, A. Battler, A. Solodky, E. Sari, N. Singh, A. Vara, A. M. Peters, A. De Belder, S. Nair, N. Ryan, R. James, S. Dizdarevic, G. Depuey, M. Friedman, R. Wray, R. Old, H. Babla, B. Chuanyong, J. Maddahi, E. Tragardh Johansson, K. Sjostrand, L. Edenbrandt, S. Aguade-Bruix, G. Cuberas-Borros, M. N. Pizzi, M. Sabate-Fernandez, G. De Leon, D. Garcia-Dorado, J. Castell-Conesa, J. Candell-Riera, D. Casset-Senon, M. Edjlali-Goujon, D. Alison, A. Delhommais, P. Cosnay, C. S. Low, A. Notghi, J. O'brien, A. C. Tweddel, N. Bingham, P. O Neil, M. Harbinson, O. Lindner, W. Burchert, M. Schaefers, C. Marcassa, R. Campini, P. Calza, O. Zoccarato, A. Kisko, J. Kmec, M. Babcak, M. Vereb, M. Vytykacova, J. Cencarik, P. Gazdic, J. Stasko, A. Abreu, E. Pereira, L. Oliveira, P. Colarinha, V. Veloso, I. Enriksson, G. Proenca, P. Delgado, L. Rosario, J. Sequeira, I. Kosa, I. Vassanyi, C. S. Egyed, G. Y. Kozmann, S. Morita, M. Nanasato, I. Nanbu, Y. Yoshida, H. Hirayama, A. Allam, A. Sharef, I. Shawky, M. Farid, M. Mouden, J. P. Ottervanger, J. R. Timmer, M. J. De Boer, S. Reiffers, P. L. Jager, S. Knollema, G. M. Nasr, M. Mohy Eldin, M. Ragheb, I. Casans-Tormo, R. Diaz-Exposito, F. J. Hurtado-Mauricio, R. Ruano, M. Diego, F. Gomez-Caminero, C. Albarran, A. Martin De Arriba, A. Rosero, R. Lopez, C. Martin Luengo, J. R. Garcia-Talavera, I. E. K. Laitinen, M. Rudelius, E. Weidl, G. Henriksen, H. J. Wester, M. Schwaiger, X. B. Pan, T. Schindler, A. Quercioli, H. Zaidi, O. Ratib, J. M. Declerck, E. Alexanderson Rosas, R. Jacome, M. Jimenez-Santos, E. Romero, M. A. Pena-Cabral, A. Meave, J. Gonzalez, F. Rouzet, L. Bachelet, J. M. Alsac, M. Suzuki, L. Louedec, A. Petiet, F. Chaubet, D. Letourneur, J. B. Michel, D. Le Guludec, A. Aktas, A. Cinar, G. Yaman, T. Bahceci, K. Kavak, A. Gencoglu, A. Jimenez-Heffernan, E. Sanchez De Mora, J. Lopez-Martin, R. Lopez-Aguilar, C. Ramos, C. Salgado, A. Ortega, C. Sanchez-Gonzalez, J. Roa, A. Tobaruela, S. V. Nesterov, O. Turta, M. Maki, C. Han, D. Daou, M. Tawileh, S. O. Chamouine, C. Coaguila, E. Mariscal-Labrador, N. Kisiel-Gonzalez, P. De Araujo Goncalves, P. J. Sousa, H. Marques, J. O'neill, J. Pisco, R. Cale, J. Brito, A. Gaspar, F. P. Machado, J. Roquette, M. Martinez, G. Melendez, E. Kimura, J. M. Ochoa, A. M. Alessio, A. Patel, R. Lautamaki, F. M. Bengel, J. B. Bassingthwaighte, J. H. Caldwell, K. Rahbar, H. Seifarth, M. Schafers, L. Stegger, T. Spieker, A. Hoffmeier, D. Maintz, H. Scheld, O. Schober, M. Weckesser, H. Aoki, I. Matsunari, K. Kajinami, M. Martin Fernandez, M. Barreiro Perez, O. V. Fernandez Cimadevilla, D. Leon Duran, E. Velasco Alonso, J. P. Florez Munoz, L. H. Luyando, C. Templin, C. E. Veltman, J. H. C. Reiber, S. Venuraju, A. Yerramasu, S. Atwal, A. Lahiri, T. Kunimasa, M. Shiba, K. Ishii, J. Aikawa, E. S. J. Kroner, K. T. Ho, Q. W. Yong, K. C. Chua, C. Panknin, C. J. Roos, J. M. Van Werkhoven, A. J. Witkowska-Grzeslo, M. J. Boogers, D. V. Anand, D. Dey, D. Berman, F. Mut, R. Giubbini, L. Lusa, T. Massardo, A. Iskandrian, M. Dondi, A. Sato, Y. Kakefuda, E. Ojima, T. Adachi, A. Atsumi, T. Ishizu, Y. Seo, M. Hiroe, K. Aonuma, M. Kruk, R. Pracon, C. Kepka, J. Pregowski, A. Kowalewska, M. Pilka, M. Opolski, I. Michalowska, Z. Dzielinska, M. Demkow, V. Stoll, N. Sabharwal, A. Chakera, O. Ormerod, H. Fernandes, M. Bernardes, E. Martins, P. Oliveira, T. Vieira, G. Terroso, A. Oliveira, T. Faria, F. Ventura, J. Pereira, S. Fukuzawa, M. Inagaki, J. Sugioka, A. Ikeda, S. Okino, J. Maekawa, T. Uchiyama, N. Kamioka, S. Ichikawa, M. Afshar, R. Alvi, N. Aguilar, R. Ippili, H. Shaqra, J. Bella, N. Bhalodkar, A. Dos Santos, M. Daicz, L. O. Cendoya, H. G. Marrero, J. Casuscelli, M. Embon, G. Vera Janavel, E. Duronto, E. P. Gurfinkel, C. M. Cortes, Y. Takeishi, K. Nakajima, Y. Yamasaki, T. Nishimura, K. Hayes Brown, F. Collado, M. Alhaji, J. Green, S. Alexander, R. Vashistha, S. Jain, F. Aldaas, J. Shanes, R. Doukky, K. Ashikaga, Y. J. Akashi, M. Uemarsu, R. Kamijima, K. Yoneyama, K. Omiya, Y. Miyake, Y. Brodov, U. Raval, A. Berezin, V. Seden, E. Koretskaya, T. A. Panasenko, S. Matsuo, S. Kinuya, J. Chen, R. J. Van Bommel, B. Van Der Hiel, P. Dibbets-Schneider, E. V. Garcia, I. Rutten-Vermeltfoort, M. M. J. Gevers, B. Verhoeven, A. B. Dijk Van, E. Raaijmakers, P. G. H. M. Raijmakers, J. E. Engvall, M. Gjerde, J. De Geer, E. Olsson, P. Quick, A. Persson, M. Mazzanti, M. Marini, L. Pimpini, G. P. Perna, C. Marciano, P. Gargiulo, M. Galderisi, C. D'amore, G. Savarese, L. Casaretti, S. Paolillo, A. Cuocolo, P. Perrone Filardi, M. Al-Amoodi, E. C. Thompson, K. Kennedy, K. A. Bybee, A. I. Mcghie, J. H. O'keefe, T. M. Bateman, R. L. F. Van Der Palen, A. M. Mavinkurve-Groothuis, B. Bulten, L. Bellersen, H. W. M. Van Laarhoven, L. Kapusta, L. F. De Geus-Oei, P. P. Pollice, M. B. Bonifazi, F. P. Pollice, I. P. Clements, D. O. Hodge, C. G. Scott, M. De Ville De Goyet, B. Brichard, T. Pirotte, S. Moniotte, R. A. Tio, A. Elvan, R. A. I. O. Dierckx, R. H. J. A. Slart, T. Furuhashi, M. Moroi, H. Hase, N. Joki, H. Masai, R. Nakazato, H. Fukuda, K. Sugi, K. Kryczka, E. Kaczmarska, J. Petryka, L. Mazurkiewicz, W. Ruzyllo, P. Smanio, E. Vieira Segundo, M. Siqueira, J. Kelendjian, J. Ribeiro, J. Alaca, M. Oliveira, F. Alves, I. Peovska, J. Maksimovic, M. Vavlukis, N. Kostova, D. Pop Gorceva, V. Majstorov, M. Zdraveska, S. Hussain, M. Djearaman, E. Hoey, L. Morus, O. Erinfolami, A. Macnamara, M. P. Opolski, A. Witkowski, V. Berti, F. Ricci, R. Gallicchio, W. Acampa, G. Cerisano, C. Vigorito, R. Sciagra', A. Pupi, H. Sliem, F. M. Collado, S. Schmidt, A. Maheshwari, R. Kiriakos, V. Mwansa, S. Ljubojevic, S. Sedej, M. Holzer, G. Marsche, V. Marijanski, J. Kockskaemper, B. Pieske, A. Ricalde, G. Alexanderson, A. Mohani, P. Khanna, A. Sinusas, F. Lee, V. A. Pinas, B. L. F. Van Eck-Smit, H. J. Verberne, C. M. De Bruin, G. Guilhermina, L. Jimenez-Angeles, O. Ruiz De Jesus, O. Yanez-Suarez, E. Vallejo, E. Reyes, M. Chan, M. L. Hossen, S. R. Underwood, A. Karu, S. Bokhari, V. Pineda, L. M. Gracia-Sanchez, A. Garcia-Burillo, K. Zavadovskiy, Y. U. Lishmanov, W. Saushkin, I. Kovalev, A. Chernishov, A. Annoni, M. Tarkia, T. Saanijoki, V. Oikonen, T. Savunen, M. A. Green, M. Strandberg, A. Roivainen, M. C. Gaeta, C. Artigas, J. Deportos, L. Geraldo, A. Flotats, V. La Delfa, I. Carrio, W. J. Laarse, M. M. Izquierdo Gomez, J. Lacalzada Almeida, A. Barragan Acea, A. De La Rosa Hernandez, R. Juarez Prera, G. Blanco Palacios, J. A. Bonilla Arjona, J. J. Jimenez Rivera, J. L. Iribarren Sarrias, I. Laynez Cerdena, A. Dedic, A. Rossi, G. J. R. Ten Kate, A. Dharampal, A. Moelker, T. W. Galema, N. Mollet, P. J. De Feyter, K. Nieman, D. Trabattoni, A. Broersen, M. Frenay, M. M. Boogers, P. H. Kitslaar, J. Dijkstra, D. A. Annoni, M. Muratori, N. Johki, M. Tokue, A. S. Dharampal, A. C. Weustink, L. A. E. Neefjes, S. L. Papadopoulou, C. Chen, N. R. A. Mollet, E. H. Boersma, G. P. Krestin, J. A. Purvis, D. Sharma, S. M. Hughes, D. S. Berman, R. Taillefer, J. Udelson, M. Devine, J. Lazewatsky, G. Bhat, D. Washburn, D. Patel, T. Mazurek, S. Tandon, S. Bansal, S. Inzucchi, L. Staib, J. Davey, D. Chyun, L. Young, F. Wackers, M. T. Harbinson, G. Wells, J. Dougan, S. Borges-Neto, H. Phillips, A. Farzaneh-Far, Z. Starr, L. K. Shaw, M. Fiuzat, C. O'connor, M. Henzlova, W. L. Duvall, A. Levine, U. Baber, L. Croft, S. Sahni, S. Sethi, L. Hermann, A. Nureldin, A. Gomaa, M. A. T. Soliman, H. A. R. Hany, F. De Graaf, A. Pazhenkottil, H. M. J. Siebelink, J. H. Reiber, M. Ayub, T. Naveed, M. Azhar, A. Van Tosh, T. L. Faber, J. R. Votaw, N. Reichek, B. Pulipati, C. Palestro, K. J. Nichols, K. Okuda, Y. Kirihara, T. Ishikawa, J. Taki, M. Yoshita, M. Yamada, A. Salacata, S. Keavey, V. Chavarri, J. Mills, H. Nagaraj, P. Bhambhani, D. E. Kliner, P. Soman, J. Heo, A. E. Iskandrian, M. Jain, B. Lin, A. Walker, C. Nkonde, S. Bond, A. Baskin, J. Declerck, M. E. Soto, G. Mendoza, M. Aguilar, S. P. Williams, G. Colice, J. R. Mcardle, A. Lankford, D. K. Kajdasz, C. R. Reed, L. Angelini, F. Angelozzi, G. Ascoli, A. Jacobson, H. J. Lessig, M. C. Gerson, M. D. Cerqueira, J. Narula, M. Uematsu, K. Kida, K. Suzuki, P. E. Bravo, K. Fukushima, M. Chaudhry, J. Merrill, A. Alonso Tello, J. F. Rodriguez Palomares, G. Marti Aguasca, S. Aguade Bruix, V. Aliaga, P. Mahia, T. Gonzalez-Alujas, J. Candell, A. Evangelista, R. Mlynarski, A. Mlynarska, M. Sosnowski, B. Zerahn, P. Hasbak, C. E. Mortensen, H. F. Mathiesen, M. Andersson, D. Nielsen, L. Ferreira Santos, M. J. Ferreira, D. Ramos, D. Moreira, M. J. Cunha, A. Albuquerque, A. Moreira, J. Oliveira Santos, G. Costa, L. A. Providencia, Y. Arita, S. Kihara, N. Mitsusada, M. Miyawaki, H. Ueda, H. Hiraoka, Y. Matsuzawa, J. Askew, M. O'connor, L. Jordan, R. Ruter, R. Gibbons, T. Miller, L. Emmett, A. Ng, N. Sorensen, R. Mansberg, L. Kritharides, T. Gonzalez, H. Majmundar, N. P. Coats, S. Vernotico, J. H. Doan, T. M. Hernandez, M. Evini, A. D. Hepner, T. K. Ip, W. A. Chalela, A. M. Falcao, L. O. Azouri, J. A. F. Ramires, J. C. Meneghetti, F. Manganelli, M. Spadafora, P. Varrella, G. Peluso, R. Sauro, E. Di Lorenzo, F. Rotondi, S. Daniele, P. Miletto, A. J. M. Rijnders, B. W. Hendrickx, W. Van Der Bruggen, Y. G. C. J. America, P. J. Thorley, F. U. Chowdhury, C. J. Dickinson, S. I. Sazonova, I. Y. U. Proskokova, A. M. Gusakova, S. M. Minin, Y. U. B. Lishmanov, V. V. Saushkin, G. Rodriguez, F. Roffe, H. Ilarraza, D. Bialostozky, A. N. Kitsiou, P. Arsenos, I. Tsiantis, S. Charizopoulos, S. Karas, R. C. Vidal Perez, M. Garrido, V. Pubul, S. Argibay, C. Pena, M. Pombo, A. B. Ciobotaru, A. Sanchez-Salmon, A. Ruibal Morell, J. R. Gonzalez-Juanatey, E. Rodriguez-Gomez, B. Martinez, D. Pontillo, F. Benvissuto, F. Fiore Melacrinis, S. Maccafeo, E. V. Scabbia, R. Schiavo, Y. Golzar, C. Gidea, J. Golzar, D. Pop-Gorceva, M. Zdravkovska, S. Stojanovski, L. J. Georgievska-Ismail, T. Katsikis, A. Theodorakos, A. Kouzoumi, M. Koutelou, Y. Yoshimura, T. Toyama, H. Hoshizaki, S. Ohshima, M. Inoue, T. Suzuki, A. Uitterdijk, M. Dijkshoorn, M. Van Straten, W. J. Van Der Giessen, D. J. Duncker, D. Merkus, G. Platsch, J. Sunderland, C. Tonge, P. Arumugam, T. Dey, H. Wieczorek, R. Bippus, R. L. Romijn, B. E. Backus, T. Aach, M. Lomsky, L. Johansson, J. Marving, S. Svensson, J. L. Pou, F. P. Esteves, P. Raggi, R. Folks, Z. Keidar, J. W. Askew, L. Verdes, L. Campos, V. Gulyaev, A. Pankova, J. Santos, S. Carmona, I. Henriksson, A. Prata, M. Carrageta, A. I. Santos, K. Yoshinaga, M. Naya, C. Katoh, O. Manabe, S. Yamada, H. Iwano, S. Chiba, H. Tsutsui, N. Tamaki, I. Vassiliadis, E. Despotopoulos, O. Kaitozis, E. Hatzistamatiou, R. Thompson, J. Hatch, M. Zink, B. S. Gu, G. D. Bae, C. M. Dae, G. H. Min, E. J. Chun, S. I. Choi, M. Al-Mallah, K. Kassem, O. Khawaja, D. Goodman, D. Lipkin, L. Christiaens, B. Bonnet, J. Mergy, D. Coisne, J. Allal, N. Dias Ferreira, D. Leite, J. Rocha, M. Carvalho, D. Caeiro, N. Bettencourt, P. Braga, V. Gama Ribeiro, U. S. Kristoffersen, A. M. Lebech, H. Gutte, R. S. Ripa, N. Wiinberg, C. L. Petersen, G. Jensen, A. Kjaer, C. Bai, R. Conwell, R. D. Folks, L. Verdes-Moreiras, D. Manatunga, A. F. Jacobson, D. Belzer, Y. Hasid, M. Rehling, R. H. Poulsen, L. Falborg, J. T. Rasmussen, L. N. Waehrens, C. W. Heegaard, J. M. U. Silvola, S. Forsback, J. O. Laine, S. Heinonen, S. Ylaherttuala, A. Broisat, M. Ruiz, N. C. Goodman, J. Dimastromatteo, D. K. Glover, F. Hyafil, F. Blackwell, G. Pavon-Djavid, L. Sarda-Mantel, L. J. Feldman, A. Meddahi-Pelle, V. Tsatkin, Y.- H. Liu, R. De Kemp, P. J. Slomka, R. Klein, G. Germano, R. S. Beanlands, A. Rohani, V. Akbari, J. G. J. Groothuis, M. Fransen, A. M. Beek, S. L. Brinckman, M. R. Meijerink, M. B. M. Hofman, C. Van Kuijk, S. Kogure, E. Yamashita, J. Murakami, R. Kawaguchi, H. Adachi, S. Oshima, S. Minin, S. Popov, Y. U. Saushkina, G. Savenkova, D. Lebedev, E. Alexandridis, D. Rovithis, C. Parisis, I. Sazonova, V. Saushkin, V. Chernov, L. Zaabar, H. Bahri, S. Hadj Ali, A. Sellem, I. Slim, N. El Kadri, H. Slimen, H. Hammami, S. Lucic, A. Peter, S. Tadic, K. Nikoletic, R. Jung, M. Lucic, K. Tagil, D. Jakobsson, S.- E. Svensson, P. Wollmer, L. Leccisotti, L. Indovina, L. Paraggio, M. L. Calcagni, A. Giordano, M. Kapitan, A. Paolino, M. Nunez, J. Sweeny, N. Kulkarni, K. Guma, Y. Akashi, M. Takano, M. Takai, S. Koh, F. Miyake, N. Torun, G. Durmus Altun, A. Altun, E. Kaya, H. Saglam, D. T. Matsuoka, A. Sanchez, C. Bartolozzi, D. Padua, G. Ponta, A. Ponte, A. Carneiro, A. Thom, R. Ashrafi, P. Garg, G. Davis, A. Falcao, M. Costa, F. Bussolini, J. A. C. Meneghetti, M. Tobisaka, E. Correia, J. W. Jansen, P. A. Van Der Vleuten, T. P. Willems, F. Zijlstra, M. Sato, K. Taniguchi, M. Kurabayashi, D. Pop Gjorcheva, M. Zdraveska-Kochovska, K. Moriwaki, A. Kawamura, K. Watanabe, T. Omura, S. Sakabe, T. Seko, A. Kasai, M. Ito, M. Obana, T. Akasaka, C. Hruska, D. Truong, C. Pletta, D. Collins, C. Tortorelli, D. Rhodes, M. El-Prince, A. Martinez-Moeller, M. Marinelli, S. Weismueller, C. Hillerer, B. Jensen, S. G. Nekolla, H. Wakabayashi, K. Tsukamoto, S. M. E. A. Baker, K. M. H. S. Sirajul Haque, A. Siddique, S. Krishna Banarjee, A. Ahsan, F. Rahman, M. Mukhlesur Rahman, T. Parveen, M. Lutfinnessa, F. Nasreen, H. Sano, S. Naito, M. L. De Rimini, G. Borrelli, F. Baldascino, P. Calabro, C. Maiello, A. Russo, C. Amarelli, P. Muto, I. Danad, P. G. Raijmakers, Y. E. Appelman, O. S. Hoekstra, J. T. Marcus, A. Boonstra, D. V. Ryzhkova, T. V. Kuzmina, O. S. Borodina, M. A. Trukshina, I. S. Kostina, H. Hommel, G. Feuchtner, O. Pachinger, G. Friedrich, A. M. Stel, J. W. Deckers, V. Gama, A. Ciarka, L. A. Neefjes, N. R. Mollet, E. J. Sijbrands, J. Wilczek, C. Llibre Pallares, O. Abdul-Jawad Altisent, H. Cuellar Calabria, P. Mahia Casado, M. T. Gonzalez-Alujas, A. Evangelista Masip, D. Garcia-Dorado Garcia, Y. Tekabe, X. Shen, Q. Li, J. Luma, D. Weisenberger, A. M. Schmidt, R. Haubner, L. Johnson, L. Sleiman, S. Thorn, M. Hasu, M. Thabet, J. N. Dasilva, S. C. Whitman, D. Genovesi, A. Giorgetti, A. Gimelli, G. Cannizzaro, F. Bertagna, G. Fagioli, M. Rossi, R. Bonini, P. Marzullo, C. A. Paterson, S. A. Smith, A. D. Small, N. E. R. Goodfield, W. Martin, S. Nekolla, H. Sherif, S. Reder, M. Yu, A. Kusch, D. Li, J. Zou, M. S. Lloyd, K. Cao, D. W. Motherwell, A. Rice, G. M. Mccurrach, S. M. Cobbe, M. C. Petrie, I. Al Younis, E. Van Der Wall, T. Mirza, M. Raza, H. Hashemizadeh, L. Santos, B. A. Krishna, F. Perna, M. Lago, M. Leo, G. Pelargonio, G. Bencardino, M. L. Narducci, M. Casella, F. Bellocci, S. Kirac, O. Yaylali, M. Serteser, T. Yaylali, A. Okizaki, Y. Urano, M. Nakayama, S. Ishitoya, J. Sato, Y. Ishikawa, M. Sakaguchi, N. Nakagami, T. Aburano, S. V. Solav, R. Bhandari, S. Burrell, S. Dorbala, I. Bruno, C. Caldarella, A. Collarino, M. V. Mattoli, A. Stefanelli, A. Cannarile, F. Maggi, V. Soukhov, S. Bondarev, A. Yalfimov, M. Khan, P. P. Priyadharshan, G. Chandok, T. Aziz, M. Avison, R. A. Smith, D. S. Bulugahapitya, T. Vakhtangadze, F. Todua, M. Baramia, G. Antelava, N.- C. Roche, P. Paule, S. Kerebel, J.- M. Gil, L. Fourcade, A. Tzonevska, K. Tzvetkov, M. Atanasova, V. Parvanova, A. Chakarova, E. Piperkova, B. Kocabas, H. Muderrisoglu, C. P. Allaart, E. Entok, S. Simsek, B. Akcay, I. Ak, E. Vardareli, M. Stachura, P. J. Kwasiborski, G. J. Horszczaruk, E. Komar, A. Cwetsch, B. Zraik, R. Morales Demori, A. D. J. Almeida, M. E. Siqueira, E. Vieira, I. Balogh, G. Kerecsen, E. Marosi, Z. S. Szelid, A. Sattar, T. Swadia, J. Chattahi, W. Qureshi, F. Khalid, A. Gonzalez, S. Hechavarria, K. Takamura, S. Fujimoto, R. Nakanishi, S. Yamashina, A. Namiki, J. Yamazaki, K. Koshino, Y. Hashikawa, N. Teramoto, M. Hikake, S. Ishikane, T. Ikeda, H. Iida, Y. Takahashi, N. Oriuchi, H. Higashino, K. Endo, T. Mochizuki, K. Murase, A. Baali, R. Moreno, M. Chau, H. Rousseau, F. Nicoud, P. Dolliner, L. Brammen, G. Steurer, T. Traub-Weidinger, P. Ubl, P. Schaffarich, G. Dobrozemsky, A. Staudenherz, M. Ozgen Kiratli, B. Temelli, N. B. Kanat, T. Aksoy, G. A. Slavich, G. Piccoli, M. Puppato, S. Grillone, D. Gasparini, S. Perruchoud, C. Poitry-Yamate, M. Lepore, R. Gruetter, T. Pedrazzini, D. Anselm, A. Anselm, H. Atkins, J. Renaud, R. Dekemp, I. Burwash, A. Guo, R. Beanlands, C. Glover, I. Vilardi, B. Zangheri, L. Calabrese, P. Romano, A. Bruno, O. C. Fernandez Cimadevilla, V. A. Uusitalo, M. Luotolahti, M. Wendelin-Saarenhovi, J. Sundell, O. Raitakari, S. Huidu, R. Gadiraju, M. Ghesani, Q. Uddin, B. Wosnitzer, N. Takahashi, E. Alhaj, A. Legasto, B. Abiri, K. Elsaban, T. El Khouly, T. El Kammash, A. Al Ghamdi, B. Kyung Deok, K. Bon Seung, Y. Sang Geun, D. Chang Min, and M. Gwan Hong

Subjects
Cardiology and Cardiovascular Medicine
Published
2011
Full Text
View/download PDF

4. Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

Author

Huibers M, Abla O, Andrés M, Balagué O, Beishuizen A, Carraro E, Chiang A, Csóka M, David BA, de Ville de Goyet M, Gilad G, Hori D, Kotecha RS, Kabickova E, Klapper W, Miakova N, Minard-Colin V, Nakazawa A, Pillon M, Rigaud C, Salaverria I, Tölle I, Verdú-Amorós J, von Mersi H, Wössmann W, Burkhardt B, and Attarbaschi A

Subjects
Child, Humans, Adolescent, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology
Published
2024
Full Text
View/download PDF

5. Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies.

Author

de Ville de Goyet M, Kicinski M, Suciu S, Vandecruys E, Uyttebroeck A, Ferster A, Freycon C, Plat G, Thomas C, Barbati M, Dresse MF, Paillard C, Pluchart C, Simon P, Chantrain C, Minckes O, van der Werff Ten Bosch J, Bertrand Y, Rohrlich P, Millot F, Paulus R, Benoit Y, and Piette C

Abstract

Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and radiotherapy. This observational retrospective study evaluated the cumulative incidence of neurological late effects among 890 childhood ALL survivors treated in EORTC CLG trials (58741, 58831/2 and 58881) between 1971 and 1998. Median follow-up was 19 years and interquartile range of the follow-up was 15-22 years. At 20 years from the end of treatment, approximately 66% of patients from the 58741 trial (accrual time: 1971-1978) and approximately 15% from the more recent trials had cognitive disturbance grade 1 or higher. Cumulative incidences at 20 years from treatment end of seizures, stroke and leukoencephalopathy were respectively 45%, 16% and 62% in study 58741, 13%, 2% and 5% in study 58831/2, and 8%, 2% and 3% in study 58881. Patients who were 10-17 years of age at diagnosis had a higher incidence of stroke and leukoencephalopathy as compared to those less than 6 years of age. Noteworthy, all neurological late effects continued to occur beyond 5 years after end of treatment. This retrospective study highlights the frequency of neurological late effects in survivors of childhood ALL. With the increase of the overall survival of ALL patients, the role and potential benefit of longitudinal neurological screening should be evaluated in further studies as these neurological late effects become an important public health challenge. This study is part of the larger EORTC CLG 58 Late Adverse Effects (LAE) study (ClinicalTrials.gov Identifier NCT01298388, date of registration February 16, 2011)., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

6. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Author

Ehrhardt MJ, Leerink JM, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, Nathan PC, Merkx R, de Baat E, Asogwa OA, Skinner R, Wallace H, Lieke Feijen EAM, de Ville de Goyet M, Prasad M, Bárdi E, Pavasovic V, van der Pal H, Fresneau B, Demoor-Goldschmidt C, Hennewig U, Steinberger J, Plummer C, Chen MH, Teske AJ, Haddy N, van Dalen EC, Constine LS, Chow EJ, Levitt G, Hudson MM, Kremer LCM, and Armenian SH

Subjects
Child, Humans, Adolescent, Young Adult, Survivors, Antibiotics, Antineoplastic adverse effects, Mitoxantrone, Neoplasms drug therapy, Neoplasms radiotherapy, Cardiomyopathies chemically induced, Cardiomyopathies diagnosis
Abstract

Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020., Competing Interests: Declaration of interests AN reports research support from Amgen; a research contract with Bristol Myers Squibb; consulting fees from AstraZeneca, Boehringer Ingelheim, and Bantam Pharmaceuticals; and participation on a data safety monitoring board for Takeda Oncology. CP reports personal honoraria and expenses for presentation at education meetings from Amgen, Incyte, Ipsen, Novartis, and Servier. LSC reports grant funding from the University of Alabama for the Children's Oncology Group Guidelines, payment or honoraria for lectures or presentations from the American Society of Hematology and the University of Miami, and participation in the National Cancer Institute PDQ Pediatric Oncology Board. EJC is the Principal Investigator on a research grant to his institution from Abbott Laboratories. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Published
2023
Full Text
View/download PDF

7. Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies.

Author

Welsch S, Sawadogo K, Brichard B, de Ville de Goyet M, Van Damme A, Boulanger C, and Lysy PA

Subjects
Adolescent, Belgium epidemiology, Blood Glucose metabolism, Child, Child, Preschool, Combined Modality Therapy adverse effects, Female, Hematologic Neoplasms complications, Humans, Hyperglycemia blood, Hyperglycemia etiology, Incidence, Infant, Infant, Newborn, Male, Retrospective Studies, Risk Factors, Hematologic Neoplasms therapy, Hyperglycemia epidemiology, Risk Assessment methods
Abstract

Background: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of our cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients., Methods: We retrospectively collected 15 years of data from paediatric patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL) immediately at cancer diagnosis. We studied risk factors for hyperglycaemia in univariate and multivariate analyses., Results: Our study cohort included 267 patients corresponding to 179 patients with ALL, 48 with NHL and 40 with HL. Eighteen per cent of ALL patients (32/179) and 17% of NHL patients (8/48) developed hyperglycaemia, with more than 61% developing hyperglycaemia within the first month of treatment. No hyperglycaemia was observed in HL patients. Multivariate analysis showed the following hyperglycaemia risk factors for ALL patients: overweight or obesity (OR 3.793) and pubertal onset (OR 4.269) at cancer diagnosis, steroid-resistant disease (OR 3.445) and hematopoietic stem cell transplant (HSCT) (OR 4.754)., Conclusion: In our cohort, 18% of patients with ALL or NHL developed early-onset hyperglycaemia after chemotherapy/radiotherapy. Patients with ALL with increased hyperglycaemia risk can be readily identified by measuring BMI and puberty stage at cancer diagnosis. Also, glucose monitoring should be reinforced when patients show steroid-resistant disease and/or require HSCT., (© 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.)

Published
2022
Full Text
View/download PDF

8. Detection of alternative lengthening of telomeres mechanism on tumor sections.

Author

Claude E, de Lhoneux G, Pierreux CE, Marbaix E, de Ville de Goyet M, Boulanger C, Van Damme A, Brichard B, and Decottignies A

Abstract

The vast majority of adult cancer cells achieve cellular immortality by activating a telomere maintenance mechanism (TMM). While this is mostly achieved by the de-silencing of hTERT telomerase gene expression, an alternative homologous recombination-based and telomerase-independent mechanism, known as ALT (Alternative Lengthening of Telomeres), is frequently activated in a subset of tumors, including paediatric cancers. Being absent from normal cells, the ALT mechanism offers interesting perspectives for new targeted cancer therapies. To date, however, the development of better translationally applicable tools for ALT detection in tumor sections is still needed. Here, using a newly derived ALT-positive cancer cell mouse xenograft model, we extensively examined how the previously known ALT markers could be used as reliable tools for ALT diagnosis in tumor sections. We found that, together with the detection of ultra-bright telomeric signals (UBS), an ALT hallmark, native telomeric FISH, that detects single-stranded C-rich telomeric DNA, provides a very sensitive and robust tool for ALT diagnosis in tissues. We applied these assays to paediatric tumor samples and readily identified three ALT-positive tumors for which the TMM was confirmed by the gold-standard C-circle amplification assay. Although the latter offers a robust assay for ALT detection in the context of research laboratories, it is more difficult to set up in histopathological laboratories and could therefore be conveniently replaced by the combination of UBS detection and native telomeric FISH., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

9. Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).

Author

Neven Q, Boulanger C, Bruwier A, de Ville de Goyet M, Meyts I, Moens L, Van Damme A, and Brichard B

Subjects
Adolescent, Adult, Alleles, Autoimmune Diseases therapy, Autoimmune Lymphoproliferative Syndrome diagnosis, Autoimmune Lymphoproliferative Syndrome etiology, Child, Child, Preschool, Combined Modality Therapy, Diagnosis, Differential, Disease Management, Female, Genetic Predisposition to Disease, Genotype, Humans, Infant, Karyotype, Male, Mutation, Myeloproliferative Disorders therapy, Phenotype, Prognosis, Skin immunology, Skin metabolism, Skin pathology, Treatment Outcome, Young Adult, Autoimmune Diseases diagnosis, Autoimmune Diseases etiology, Autoimmunity genetics, Disease Susceptibility, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders etiology, ras Proteins genetics
Abstract

Ras-associated autoimmune leukoproliferative disorder (RALD) is a clinical entity initially identified in patients evaluated for an autoimmune lymphoproliferative syndrome (ALPS)-like phenotype. It remains a matter of debate whether RALD is a chronic and benign lymphoproliferative disorder or a pre-malignant condition. We report the case of a 7-year-old girl diagnosed with RALD due to somatic KRAS mutation who progressed to a juvenile myelomonocytic leukemia phenotype and finally evolved into acute myeloid leukemia. The case report prompted a literature review by a search for all RALD cases published in PubMed and Embase. We identified 27 patients with RALD. The male-to-female ratio was 1:1 and median age at disease onset was 2 years (range 3 months-36 years). Sixteen patients (59%) harbored somatic mutations in KRAS and 11 patients (41%) somatic mutations in NRAS. The most common features were splenomegaly (26/27 patients), autoimmune cytopenia (15/16 patients), monocytosis (18/24 patients), pericarditis (6 patients), and skin involvement (4 patients). Two patients went on to develop a hematopoietic malignancy. In summary, the current case documents an additional warning about the long-term risk of malignancy in RALD.

Published
2021
Full Text
View/download PDF

10. B-acute Lymphoblastic Leukemia With Hypereosinophilia Associated With Severe Cardiac Complications: A Clinical Case.

Author

Lahfafa A, de Ville de Goyet M, Boulanger C, Defour JP, Detaille T, Van Damme A, and Brichard B

Subjects
Adolescent, Cardiomyopathies etiology, Humans, Hypereosinophilic Syndrome etiology, Lymphoma, B-Cell complications, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Prognosis, Cardiomyopathies pathology, Hypereosinophilic Syndrome pathology, Lymphoma, B-Cell pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
Abstract

Hypereosinophilia (HE) is rare but often secondary to a nonhematologic disease such as allergic disorders and parasitic infections. HE can also be associated with hematologic malignancies and be the result of a clonal proliferation or reactive to another hematologic condition. Association of HE with acute lymphoblastic leukemia (ALL) is rare in children. We reported a case of a teenager presented with HE secondary to B-ALL who experienced severe cardiac complications with severe absolute eosinophil count. We compared his clinical evolution with other published cases and we reported 2 mutations linked to B-ALL never described before in this context.

Published
2021
Full Text
View/download PDF

11. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.

Author

Balbeur S, Dumortier A, Mergen J, Libbrecht L, Torbenson M, Boulanger C, de Ville de Goyet M, Van Damme A, and Brichard B

Subjects
Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular genetics, Female, Gene Rearrangement, Humans, Neoplasms, Unknown Primary drug therapy, Neoplasms, Unknown Primary genetics, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms genetics, Prognosis, Carcinoma, Hepatocellular secondary, Cyclic AMP-Dependent Protein Kinase Catalytic Subunits genetics, HSP40 Heat-Shock Proteins genetics, Neoplasms, Unknown Primary pathology, Peritoneal Neoplasms secondary
Abstract

Fibrolamellar carcinoma (FLC) is a rare variant of hepatocellular carcinoma, occurring in children and young adults without underlying liver disease. The diagnosis is based on morphological characteristics of the tumor, supplemented by immunohistochemistry and/or genetic testing. Recently, the presence of a characteristic DNAJB1-PRKACA fusion gene has been associated with FLC. Herein, we report a case of FLC presenting as peritoneal carcinomatosis in a 14-year-old female. Interestingly, no liver tumor was seen on imaging, and an alternative possibility is that the tumor arose outside the liver as a hepatoid carcinoma with fibrolamellar features., (© 2019 Wiley Periodicals, Inc.)

Published
2020
Full Text
View/download PDF

12. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.

Author

de Ville de Goyet M, Detaille T, and Godefroid N

Subjects
Atypical Hemolytic Uremic Syndrome diagnosis, Child, Preschool, Female, Hemolytic-Uremic Syndrome diagnosis, Humans, Infant, Male, Antibodies, Monoclonal, Humanized therapeutic use, Atypical Hemolytic Uremic Syndrome drug therapy, Complement Inactivating Agents therapeutic use, Hemolytic-Uremic Syndrome drug therapy
Abstract

Typical hemolytic uremic syndrome (HUS) in children is caused mostly by Escherichia coli 0157:H7 in our country. Atypical HUS (aHUS) causes include Streptococcus pneumoniae, methyl malonic aciduria, deficiency of ADAMST 13, and genetic or acquired disorder of the complement. Treatment of HUS relies on supportive measures while treatment of aHUS includes plasmapheresis and specific treatments. Recently, eculizumab has been proposed for the treatment of aHUS and many clinicians now believe that eculizumab should be the first-line standard of care. The purpose of this article is to illustrate the difficulties in the diagnostic process of HUS and therefore the subsequent problem to promptly choose the appropriate treatment. To date, workup of HUS continues to take many days leaving the clinicians with a choice between several therapeutic options. With the emergence of eculizumab, it becomes crucial to find faster diagnostic tools and to adapt HUS treatment protocols. We reported here clinical cases where eculizumab use was probably not appropriate once the correct diagnosis of typical HUS was made and cases where it would have been useful because of the late diagnosis of aHUS.

Published
2019
Full Text
View/download PDF

13. Multiple Epstein-Barr Virus-associated Smooth Muscle Sarcomas of the Gut in a Child Treated for Acute Lymphoblastic Leukemia.

Author

Boulanger C, de Ville de Goyet M, de Magnée C, Dupont S, Galant C, Van Damme A, and Brichard B

Subjects
Child, Humans, Male, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Sirolimus administration & dosage, Epstein-Barr Virus Infections pathology, Epstein-Barr Virus Infections therapy, Herpesvirus 4, Human, Intestinal Neoplasms pathology, Intestinal Neoplasms therapy, Muscle Neoplasms pathology, Muscle Neoplasms therapy, Muscle, Smooth pathology, Sarcoma diagnostic imaging, Sarcoma therapy
Abstract

A 7-year-old boy with a history of low-risk acute lymphoblastic leukemia developed multiple intussusceptions shortly after the end of maintenance therapy. Explorative laparotomy showed >10 polyps in the small intestine. Histologic examination revealed intestinal smooth muscle sarcomas associated with Epstein-Barr virus. The patient recovered well after partial cuneiform resection of the largest polyps and treatment with sirolimus. This case report indicates that these tumors may arise even after moderate transient immunosuppression and that association with acute lymphoblastic leukemia is possible although rarely described. We discuss the potential benefit of the mTor/Akt signal inhibitors as treatment for these tumors.

Published
2019
Full Text
View/download PDF

15. Prospective cardiac MRI for the analysis of biventricular function in children undergoing cancer treatments.

Author

de Ville de Goyet M, Brichard B, Robert A, Renard L, Veyckemans F, Vanhoutte L, and Moniotte S

Subjects
Adolescent, Adult, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Neoplasm Staging, Neoplasms pathology, Prognosis, Prospective Studies, Ventricular Dysfunction, Left etiology, Ventricular Dysfunction, Right etiology, Young Adult, Anthracyclines adverse effects, Antibiotics, Antineoplastic adverse effects, Chemoradiotherapy adverse effects, Magnetic Resonance Imaging methods, Neoplasms therapy, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Right diagnosis
Abstract

Background: Cardiotoxicity is one of the most serious long-term complications in childhood cancer survivors. Measurement of the left ventricular ejection and shortening fraction remains the most common screening tool for cardiac systolic dysfunction. However, M-mode echocardiography can be viewed as a crude approach as refined strategies are now available. The aim of this prospective study was to determine the role of cardiac MRI in the detection of subclinical left or right ventricular dysfunction as well as the prevalence of myocardial scaring in patients undergoing cancer treatments., Procedure: Eighty-one children were enrolled in a pre-chemotherapy and then in a yearly protocol including a: (i) clinical evaluation; (ii) laboratory evaluation; (iii) electrocardiogram; (iv) echocardiogram; and (v) a cardiac magnetic resonance imaging (cMRI)., Results: Early left ventricular systolic dysfunction was only detected in two patients. The entire cohort presented a significant increase of the left atrial volume as measured by cMRI. This finding correlated with the total cumulative dose of anthracyclines (r = 0.34; P < 0.05) and the mean left ventricular radiation dose (r = 0.86; P < 0.05). We also observed a mild increase of myocardial scaring, similarly correlated to the radiation dose (r = 0.85; P < 0.05)., Conclusions: Screening tools for late-onset cardiomyopathy secondary to cancer treatment are lacking. Our findings support the use of cMRI for the evaluation of the left atrial volume, as an early marker of diastolic dysfunction, and myocardial delayed enhancement, as a marker of myocardial fibrosis and scaring. Longer follow-up and larger studies are still needed to better define the role of cMRI in the evaluation of childhood cancer survivors., (© 2015 Wiley Periodicals, Inc.)

Published
2015
Full Text
View/download PDF

16. Iron overload in children undergoing cancer treatments.

Author

de Ville de Goyet M, Moniotte S, Robert A, Dupont S, Vermylen C, Veyckemans F, and Brichard B

Subjects
Adolescent, Child, Child, Preschool, Female, Ferritins blood, Humans, Infant, Male, Prospective Studies, Iron Overload epidemiology, Iron Overload etiology, Neoplasms therapy, Transfusion Reaction
Abstract

Background: Iron overload is responsible for severe morbidity and mortality in polytransfused patients. Although repeated blood transfusions are needed during the treatment of most cancers, pediatric patients are not routinely screened for subsequent iron overload., Procedure: Seventy-five patients were identified as candidates for cancer treatment and enrolled prospectively in a yearly protocol including a cardiac and liver magnetic resonance imaging coupled with ferritin level measurements. Patients were divided into four groups using the intensity of treatment rating (ITR-3)., Results: Fifty-nine patients reached 1-year of follow-up and liver iron overload was found in up to 66% of them. Such overload correlated with the total volume of red blood cells transfused and persisted at least 2 years after the initiation of therapy. Moderate myocardial overload was also, but less frequently (14%), observed in these patients., Conclusions: Our study demonstrated that severe liver iron overload as well as moderate myocardial iron overload can be found 1 year after cancer treatment and that this overload persists overtime. The patients with higher ITR and those who have received more than a liter of blood red cells per square meter, regardless of their diagnosis or ITR, are at risk of iron overload and should be screened carefully., (Copyright © 2013 Wiley Periodicals, Inc.)

Published
2013
Full Text
View/download PDF

17. Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up.

Author

de Ville de Goyet M, Moniotte S, and Brichard B

Subjects
Adolescent, Adult, Cardiovascular Diseases mortality, Child, Child, Preschool, Follow-Up Studies, Humans, Infant, Male, Neoplasms diagnosis, Neoplasms mortality, Cardiovascular Diseases diagnosis, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Monitoring, Physiologic methods, Neoplasms therapy
Abstract

Therapeutic advances in paediatric oncology allowed increasing numbers of children to survive until adulthood. However, chemotherapy and radiotherapy are potentially cardiotoxic and contribute to a significant morbidity and mortality, cardiovascular events remaining the leading cause of death among survivors. This review summarizes the physiopathology of treatment-related cardiovascular diseases, their incidence, and the risk factors associated with each specific therapy. Few studies have investigated the cardiac outcomes of adult surviving from childhood cancers but all demonstrated a substantial risk for late cardiac effects. Cardiovascular monitoring, prevention, and early detection of cardiac dysfunction are, therefore, the keystones of an improved long-term outcome.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results